Full Length Research Paper
References
|
Adegbola RA, Falade AG, Sam BE, Aidoo M, Baldeh I, Hazlett D, Whittle H, Greenwood BM, Mulholland EK (1994). The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr. Infect. Dis. J. 13(11):975-982. |
|
|
Baker JT, Borris RP, Carté B, Cordell GA, Soejarto DD, Cragg GM, Gupta MP, Iwu MM, Madulid DR, Tyler VE (1995). Natural product drug discovery and development: new perspectives on international collaboration. J. Nat. Prod. 58(9):1325-1357. |
|
|
Collins PL, McIntosh K, Chanock RM (1996). Respiratory syncytial virus. In: B. N. Fields (ed.), Fields virology. New York: Raven Press, 1313-1351. |
|
|
Esimone CO, Eck G, Duong TN, Uberla K, Proksch P, Grunwald T (2008). Potential anti-respiratory syncytial virus lead compounds from Aglaia species. Pharmazie 63:1-6. |
|
|
Esimone CO, Omobowajo OR, Sowemimo AA, Proksch P (2007). Single-cycle vector-based antiviral screening assays for high throughput evaluation of potential anti-HIV medicinal plants: a pilot study on some Nigerian herbs. Recent Prog. Med. Plant Res. 19:49-60. |
|
|
Golankiewicz B, Januszczyk P, Ikeda S, Balzarini J, DeClercq E (1995). Synthesis and anti-viral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9 dideazapurine) derivatives. J. Med. Chem. 38:3558-3565. |
|
|
Hall CB (1994). Prospects for a respiratory syncytial virus vaccine. Science 265:1393-1394. |
|
|
Jorquera PA Tripp RA (2017). Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev. Respir. Med. 11(8):609-615. |
|
|
Kneyber MCJ, Moll HA, de Groot R (2000). Treatment and prevention of respiratory syncytial virus infection. Eur. J. Pediatr. 159(6):399-411. |
|
|
Kott V, Barbini L, Cruanes M, de D Munoz J, Vivot E, Crua-es J, Martino V, Ferraro G, Cavallaro L, Campos R (1999). Anti-viral activity in Argentine medicinal plants. J. Ethnopharmacol. 64:79-84. |
|
|
Lai D, Odimegwu DC, Esimone C, Grunwald T, Proksch P (2013). Phenolic Compounds with in vitro activity against Respiratory Syncytial Virus from the Nigerian Lichen Ramalina farinacea. Planta Med. 79:1-7. |
|
|
Lafeuillade A, Hattinger G, Chadapaud S (2001). Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357:280-281. |
|
|
Mechanisms of Respiratory Syncytial Virus (RSV) Infection and Disease Severity. National Institutes of health (NIH), last update September 20, 2011. |
|
|
Martin WW, Mulholland EK, Greenwood BM (1998). Respiratory syncytial virus infection in tropical and developing countries. Trop. Med. Int. Health 3(4):268-280. |
|
|
Noundou XS, Krause RWM, van Vuuren SF, Ndinteh DT, Olivier DK (2014). Antibacterial activity of the roots, stems and leaves of Alchornea floribunda. J. Ethnopharmacol. 151 (2):1023-1027. |
|
|
Noundou XS, Krause RWM, van Vuuren SF, Ndinteh DT, Olivier DK (2016). Antibacterial effects of Alchornea cordifolia (Schumach. and Thonn.) Müll. Arg extracts and compounds on gastrointestinal, skin, respiratory and urinary tract pathogens. J. Ethnopharmacol. 179:76-82. |
|
|
Nwankwo MU, Okuonghae HO, Currier G, Schuit KE (1994). Respiratory syncytial virus in malnourished children. Ann. Trop. Paed. 14:125-130. |
|
|
Nworu CS, Vladimir T, Okoye FBC, Akah PA, Esimone CO, Überla K (2010). Activation of murine lymphocytes and modulation of macrophage functions by fractions of Alchornea cordifolia (Euphorbiaceae) leaf extract. Immunopharmacol. Immunotoxicol. 32(1):28-36. |
|
|
Odimegwu DC, Grunwald T, Esimone CO (2011). Anti-Respiratory Syncytial Virus Agents from Phytomedicine. In: Human Respiratory Syncytial Virus Infection (ed) Bernhard Resch. InTech, Bosnia 179-196. |
|
|
Okoye FBC, Osadebe PO, Proksch P, Edrada-Ebel RA, Nworu CS, Esimone CO (2010). Anti-inflammatory and Membrane-stabilizing Stigmastane Steroids from Alchornea floribunda Leaves. Planta Med. 76:172-177. |
|
|
Okoye FBC, Odimegwu DC, Anyasor CN, Ajaghaku DL, Gugu TH, Osadebe PO, Proksch P (2015). A new antioxidant and antimicrobial compound isolated from Alchornea cordifolia leaves. Afri. J. Pharm. Res. Dev. 7(2):87-94. |
|
|
Orhan DD, Özçelik B, Özgen S, Ergun F (2010). Antibacterial, antifungal, and antiviral activities of some flavonoids. Microbiol. Res. 165(6):496-500. |
|
|
Osadebe PO, Okoye FBC (2003). Anti-inflammatory effects of methanolic extracts and fractions of Alchornea cordifolia. J. Ethnopharmacol. 89:19-24. |
|
|
Peltola V, Ruuskanen O (2008). Respiratory Viral Infections in Developing Countries: Common, Severe, and Unrecognized. Clin. Infect. Dis. 46(1):58-60. |
|
|
Seetharama RKS, Narayana K (2005). In vivo chromosome damaging effects of an inosine monophosphate dehydrogenase inhibitor: Ribavirin in mice. Indian J. Pharmacol. 37:90-95. |
|
|
Semple SJ, Reynolds GD, O'Leary GD, Flower RLP (1998). Screening of Australian medicinal plants for anti-viral activity. J. Ethnopharmacol. 60:163-72. |
|
|
Simões EAF, DeVincenzo JP, Boeckh M, Bont L, Crowe JE, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ (2015). Challenges and opportunities in developing respiratory syncytial virus therapeutics. J. Infect. Dis. 211(1):S1-S20. |
|
|
Sindambiwe JB, Calomme M, Cos P, Totte J, Pieters L, Vlietinck A, Vanden BD (1999). Screening of seven selected Rwandan medicinale plants for antimicrobial and anti-viral activities. J. Ethnopharmacol. 65:71-77. |
|
|
Ternette N, Tippler B, Uberla K, Grunwald T (2007). Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25:7271-7279. |
|
|
Tregoning JS, Schwarze J (2010). Respiratory viral infections in infancy: causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. 23:74-98. |
|
|
Wang H, Ooi EV, Ang PO (2008). Antiviral activities of extracts from Hong Kong seaweeds. J. Zhejiang Univ. Sci. B. 9(12):969-976. |
|
|
Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr., Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR (2000). Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182(5):1331-1342. |
|
|
Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ (2002). Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76:5654-5666. |
|
|
Zakaryan H, Arabyan E, Oo A, Zandi K (2017). Flavonoids: promising natural compounds against viral infections. Arch. Virol. 162(9):2539-2551. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
